LSD Chemical Structure & Formula

LSD Chemical Structure & Formula: A Complete Scientific Breakdown

Quick Summary:  The LSD molecule — formally lysergic acid diethylamide, designated LSD-25 — has the molecular formula C₂₀H₂₅N₃O and a tetracyclic ergoline scaffold with two stereocenters that determine psychoactivity. This article breaks down exactly what the lsd chemical structure looks like, why it matters pharmacologically, and what a 2017 landmark crystal structure in Cell revealed about how this molecule produces effects that outlast its plasma half-life by hours.

When pharmacologists and neuroscientists talk about the lsd molecule, they are talking about one of the most precisely studied structures in all of psychopharmacology. The lsd formula C₂₀H₂₅N₃O encodes 20 carbons, 25 hydrogens, 3 nitrogens, and 1 oxygen — but those atoms are arranged in a way that produces effects at doses of 75 to 200 micrograms. Understanding the lsd structure, and specifically what makes it so potent and so long-lasting, requires looking at three things: the ring system, the stereocenters, and how the molecule physically interacts with its receptor.

▲ The LSD-25 molecule: C₂₀H₂₅N₃O, MW 323.43 g/mol, CAS 50-37-3. The four-ring ergoline scaffold (A-D), indole system (rings A+B), and C-8 diethylamide pharmacophore are highlighted. Only the (5R,8R) d-LSD stereoisomer is psychoactive. Source: PubChem CID 5761; NIST WebBook; ChemSpider 5558.

The LSD Formula: What C₂₀H₂₅N₃O Actually Tells You

The lsd formula C₂₀H₂₅N₃O is registered in PubChem as CID 5761 and carries CAS number 50-37-3. Molecular weight: 323.43 g/mol. IUPAC name, as documented by NIST and DrugBank: (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide. The InChIKey — the standard chemical fingerprint used for database lookup — is VAYOSLLFUXYJDT-RDTXWAMCSA-N. Alternate systematic names include (4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[7.6.1.0²‧⁷.0¹²ⁱ⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide per ChemSpider and DrugBank.

What the lsd formula reveals immediately: three nitrogen atoms and one oxygen. Two nitrogens sit within the ring system — N-1 in the indole and N-6 in the piperidine ring. The third is the amide nitrogen in the diethylamide group. The single oxygen is the carbonyl of that amide. This arrangement — a rigid tetracyclic scaffold terminated by a flexible diethylamide — is precisely what makes LSD-25 fit the 5-HT2A serotonin receptor orthosteric pocket with such high affinity (Ki approximately 4 nM, per Grokipedia/DrugBank).

✔ KEY FACT  The lsd formula C₂₀H₂₅N₃O is shared by several inactive stereoisomers: iso-LSD, l-LSD, and l-iso-LSD (Wikipedia). The same molecular formula, different three-dimensional arrangements — and only one of the four possible stereoisomers is psychoactive. This is one of the clearest examples in pharmacology of how stereochemistry determines biological activity.

The LSD Chemical Structure: Four Rings, Two Stereocenters

The lsd chemical structure is built on a tetracyclic ergoline scaffold — four interconnected rings that form the rigid backbone of the molecule. As documented by Wikibooks’ Structural Biochemistry reference and ChemSpider, this scaffold is classified as an organic heterotetracyclic compound and an ergoline alkaloid (ChEBI: 6605). Each ring has a specific role in how the molecule is oriented and recognized by receptors:

  • Ring A (benzene): The aromatic base of the indole system. Houses the indole nitrogen N-1. Edge-to-face aromatic contacts with phenylalanines F340 and F341 in the 5-HT2A receptor binding pocket, as revealed by Wacker et al. (2017).
  • Ring B (pyrrole): Fused to ring A to form the indole bicyclic unit. The shared indole scaffold with tryptamine and serotonin explains LSD’s high serotonin receptor affinity — similar dipole moments (serotonin 2.98 D, LSD 3.04 D) allow both to fit the same binding pocket (Wikibooks Structural Biochemistry).
  • Ring C (cyclohexene): The C9=C10 double bond within this ring locks the molecule into a specific three-dimensional shape critical for receptor binding.
  • Ring D (piperidine): Contains N-6 (N-methyl group) and the two stereocenters, C-5 and C-8. The diethylamide group hangs off C-8 — this is the pharmacophore.

The Two Stereocenters: Why Geometry Decides Everything

LSD-25 has two chiral centers at C-5 and C-8, giving rise to four possible stereoisomers. As documented by Wikipedia, Wikibooks, and PubChem, only the d-LSD form with (5R,8R) absolute configuration is psychoactive. The (5R) center corresponds, retrosynthetically, to the same configuration as the alpha carbon of L-tryptophan — the amino acid from which the ergoline scaffold is biosynthesized in Claviceps purpurea. The 5S enantiomers (l-LSD and l-iso-LSD) do not exist in nature and are not formed during synthesis from d-lysergic acid (Wikipedia). Iso-LSD (5R,8S) — the C-8 epimer — is a constant concern during synthesis and storage because the C-8 proton is acidic and easily removed under basic conditions, causing rapid equilibration between d-LSD and iso-LSD. Non-psychoactive iso-LSD produced during synthesis is separated by chromatography and can be re-isomerized to d-LSD under controlled acidic conditions. A racemic mixture of d-LSD and l-LSD shows only half the potency of pure d-LSD (Wikibooks Structural Biochemistry).

Physical Properties of the LSD Molecule

In its pure crystalline form — the salt LSD tartrate used in pharmaceutical and research contexts — the lsd molecule has several distinctive physical properties documented across PubChem, NIST, Wikibooks, and Wikipedia:

  • Appearance: White to slightly yellowish crystalline solid; odorless and tasteless in water solution
  • Solubility: Freely soluble in water (water-soluble crystal per Wikibooks); also soluble in ethanol and methanol
  • UV fluorescence: Glows bluish-white under UV light — a property exploited in HPLC fluorescence detection and forensic identification
  • Triboluminescence: Pure LSD salts emit small flashes of white light when shaken in the dark (Wikipedia)
  • Light sensitivity: Degraded rapidly by UV exposure — standard laboratory and pharmaceutical storage uses amber glass in cool, dark conditions
  • Chemical stability: The main degradation pathways are moisture, oxidation, light, and heat. In dry, cold, dark storage, LSD is stable for years
  • Dipole moment: 3.04 D — nearly identical to serotonin (2.98 D), which accounts for LSD’s remarkable fit to serotonin receptors (Wikibooks Structural Biochemistry)

▲ Crystal structure of the LSD-bound 5-HT2B receptor (PDB: 5TVN), and 5-HT2A/LSD complex (Kim et al., 2020). The extracellular loop 2 (EL2) forms a lid over the bound LSD molecule — the structural basis for LSD’s exceptionally slow dissociation rate and extended duration of effects. Sources: Wacker et al. (Cell, 2017); Kim et al. (Cell, 2020); PMC5289311.

How the LSD Structure Drives Its Unique Pharmacology

Understanding the lsd structure is not just academic — it explains why LSD-25 behaves so differently from structurally related compounds. Albert Hofmann synthesized 24 other lysergamide derivatives before LSD-25; none showed the same potency. The structural difference often came down to the diethylamide group. The 2017 crystal structure published in Cell by Daniel Wacker, David E. Nichols, Bryan L. Roth, and colleagues (University of North Carolina Chapel Hill; Stanford; UCSF) provided the first atomic-resolution view of LSD bound to a human serotonin receptor (5-HT2B, a structural model for the primary target 5-HT2A). The key finding was both unexpected and immediately explanatory.

The lsd molecule is anchored in the receptor’s orthosteric binding pocket by a conserved salt bridge between the ring nitrogen of the ergoline system and aspartate D135 in transmembrane helix III. The ergoline ring system forms edge-to-face aromatic contacts with phenylalanines F340 and F341 in helix VI. But what makes LSD-25 unique is what happens to the binding pocket entrance: extracellular loop 2 (EL2) of the receptor closes over the bound LSD like a lid, physically preventing it from leaving the pocket quickly.

CLINICAL INSIGHT:  LSD’s plasma half-life is approximately 3.6 hours (Dolder et al., 2015) — yet subjective effects persist for 8 to 15 hours. Wacker et al. (2017) provided the molecular explanation: the EL2 lid slows LSD’s dissociation from the 5-HT2A receptor dramatically. When a mutation was introduced to increase lid mobility, LSD’s dissociation rate increased roughly 10-fold and its β-arrestin2 recruitment was selectively reduced. The lid is not a passive feature — it actively drives the signaling profile and duration of LSD’s effects.

The diethylamide configuration at C-8, the component that makes LSD distinct from simpler lysergamides like LSA, is critical for this receptor interaction. Wacker et al. showed that the diethylamide adopts a specific conformation when bound to 5-HT2B that matches the (S,S)-azetidide constrained analog — and that this conformation is essential for LSD’s β-arrestin-biased signaling. A 2020 follow-up by Kim, Che, Wacker, Roth, and colleagues at UNC-Chapel Hill and Stanford published the crystal structure of LSD bound directly to its primary target, 5-HT2A, confirming the lid mechanism and identifying a unique residue S242 in helix V specific to 5-HT2A that extends LSD’s action further still.

Conclusion: Actionable Takeaways

  • The lsd formula C₂₀H₂₅N₃O has molecular weight 323.43 g/mol and CAS 50-37-3. It is registered in PubChem as CID 5761. The IUPAC name is (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide.
  • The lsd chemical structure is a tetracyclic ergoline scaffold (rings A-D). The indole unit (rings A+B) shares structural features with serotonin — near-identical dipole moments (3.04 D vs 2.98 D) explain LSD’s high 5-HT2A affinity.
  • The lsd structure has two stereocenters at C-5 and C-8. Only (+)-d-LSD-25 with (5R,8R) absolute configuration is psychoactive. Iso-LSD (5R,8S) and l-LSD are inactive. A racemic mixture has half the potency of pure d-LSD.
  • The diethylamide group at C-8 is the pharmacophore. Its precise conformation inside the 5-HT2A binding pocket, stabilized by the EL2 lid, is the structural basis for LSD-25’s extended duration — hours beyond what its plasma half-life would predict.
  • The 2017 Wacker et al. (Cell) and 2020 Kim et al. (Cell) crystal structures provided the first atomic-resolution explanations for LSD-25’s slow dissociation, β-arrestin-biased signaling, and unusually long receptor residence time — making the lsd molecule the most structurally characterized psychedelic drug in existence.

About the Author

👤  Dr. Sarah Chen, PharmD, PhD Clinical Pharmacologist | Psychedelic Research Specialist | University of California, San Francisco  Dr. Sarah Chen holds a Doctor of Pharmacy from UCSF and a PhD in Pharmacology from Johns Hopkins University. Her research focuses on the clinical pharmacology of serotonergic compounds, including published work on ergoline alkaloid structure-activity relationships. She draws directly from primary literature: PubChem, NIST, DrugBank, Cell, and PMC peer-reviewed sources. No financial relationships with companies developing psychedelic therapies.

References

1. PubChem. (+)-Lysergic acid diethylamide. CID 5761. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/5761

2. NIST WebBook. D-Lysergic acid N,N-diethylamide. CAS 50-37-3. https://webbook.nist.gov/cgi/cbook.cgi?ID=50-37-3

3. DrugBank. Lysergic acid diethylamide. DB04829. https://go.drugbank.com/drugs/DB04829

4. ChemSpider. Lysergic acid diethylamide. ID 5558. https://www.chemspider.com/Chemical-Structure.5558.html

5. Wacker, D., Wang, S., McCorvy, J.D., Betz, R.M., Venkatakrishnan, A.J., Levit, A., … Roth, B.L. (2017). Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell, 168(3), 377–389.e12. doi:10.1016/j.cell.2016.12.033. PMC5289311.

6. Kim, K., Che, T., Panova, O., DiBerto, J.F., Lyu, J., Krumm, B.E., … Roth, B.L. (2020). Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 182(6), 1574–1588.e19. doi:10.1016/j.cell.2020.08.024

7. Nichols, D.E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. doi:10.1124/pr.115.011478

8. Passie, T., Halpern, J.H., Stichtenoth, D.O., Emrich, H.M., & Hintzen, A. (2008). The pharmacology of LSD: A review. CNS Neuroscience & Therapeutics, 14(4), 295–314. doi:10.1111/j.1755-5949.2008.00059.x

9. Dolder, P.C., Schmid, Y., Steuer, A.E., Kraemer, T., Rentsch, K.M., Hammann, F., & Liechti, M.E. (2015). Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects. Clinical Pharmacokinetics, 56(10), 1219–1230.

10. Wikibooks. Structural Biochemistry / Lysergic acid diethylamide. https://en.wikibooks.org/wiki/Structural_Biochemistry/Lysergic_acid_diethylamide

11. Wikipedia. (2026). LSD. https://en.wikipedia.org/wiki/LSD

12. Tuck, J.R., Dunlap, L.E., & Olson, D.E. (2023). Synthetic strategies toward LSD. Journal of Organic Chemistry, 88(19), 13712–13719. doi:10.1021/acs.joc.3c01363